| Code | 5160E | ||||||||||
| MA number | 29/0271/23-S | ||||||||||
| Product Form: | tbl 100x300 mg (blis.PVDC/PVC/Al) | ||||||||||
| MA Status: | R - Valid Marketing Authorisation | ||||||||||
| Type of procedure: | Decentralised | ||||||||||
| MAH, country: | Medreg s.r.o., Czechia | ||||||||||
| Therapeutic Class: | 29 - ANTIRHEUMATICA, ANTIPHLOGISTICA, ANTIURATICA | ||||||||||
| ATC: |
|
||||||||||
| Shelf life: | 36 | ||||||||||
| Container: | blister PVDC/PVC/Al | ||||||||||
| Route of admin.: | Oral use |
| Prescription Status: | Medicinal product subject to medical prescription. |
| Legal basis: | Article 10(1) generic application |
| MA issued: | 03.01.2024 |
| Validity: | 03.01.2029 |
| Pediatric posology: | Yes |
| SPC: |
SPC_Allopurinol Medreg 300 mg_04.2025.pdf
|
| PIL: |
PIL_Allopurinol Medreg 300 mg_04.2025.pdf
|
| Safety feature | Yes |
| Data update: | 05.01.2024 |
